TriangleCD22 CAR-transduced T cells (NCT07328503)
CD22 CAR-transduced T cells trial for Acute Lymphoblastic Leukemia (NCT07328503). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 3–65 with previously relapsed or refractory B-cell ALL, now in MRD-negative remission after CD19 CAR T treatment 2–7 months earlier. Prior CD19/CD22 expression is required; donor transplant must be unsuitable or declined.
The idea: give T cells engineered to target CD22 to try to extend remission. Cell collection, if needed, precedes fludarabine/cyclophosphamide preparation and an intravenous CAR T infusion.
This phase 2 study plans 20 patients. Sara Silbert leads at the NIH Clinical Center in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.